The effect of Xiaoaiping combined with camrelizumab on serum VEGF and tumor markers in advanced esophageal cancer
10.3969/j.issn.1673-9701.2024.09.017
- VernacularTitle:消癌平联合卡瑞利珠单抗对晚期食管癌血VEGF及肿瘤标志物的影响
- Author:
Tao LIU
1
;
Jiali WANG
2
Author Information
1. Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China; Department of Cardiothoracic Vascular Surgery, Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530201, Guangxi, China
2. Department of Cardiothoracic Vascular Surgery, Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530201, Guangxi, China
- Publication Type:Journal Article
- Keywords:
Xiaoaiping;
Camrelizumab;
Esophageal cancer;
VEGF;
Tumor marker
- From:
China Modern Doctor
2024;62(9):71-73
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of Xiaoaiping and camrelizumab on vascular endothelial growth factor(VEGF)and tumor markers in patients with advanced esophageal cancer.Methods A total of 43 patients with advanced esophageal cancer who were treated in the First Affiliated Hospital of Guangxi Medical University and Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine from March 2020 to March 2022 were selected and divided into control group and combined treatment group according to the random number table method.Both groups were treated with camrelizumab immunotherapy,and the patients in combined treatment group were also treated with Xiaoaiping injection until disease progression.The levels of VEGF and tumor markers in two groups were detected after the first cycle,the third cycle,the sixth cycle,the ninth cycle and the seventeenth cycle of treatment.Results The levels of VEGF,carbohydrate antigen 125(CA125),carbohydrate antigen 199(CA199)and carcinoembryonic antigen(CEA)in the first cycle and the third cycle in two groups had no significant difference before and after treatment(P>0.05);There was no significant difference in CA125,CA199 and VEGF levels between two groups in the 6th cycle(P>0.05);There was a significant difference in CEA level between two groups(P<0.05);The levels of VEGF,CA125,CA199 and CEA in combined treatment group were significantly lower than those in control group at the 9th cycle and the 17th cycle(P<0.05).Conclusion Xiaoaiping combined with camrelizumab has a good clinical effect on patients with advanced esophageal cancer,which can reduce the levels of VEGF and tumor markers in patients.
